Measuring Microdose ABY-029 Fluorescence Signal in a Primary Human Soft-tissue Sarcoma Resection

Overview

Journal Proc SPIE Int Soc Opt Eng

Date 2019 Oct 10

PMID 31595101

Citations 11

Authors

Kimberley S Samkoe

Hira Shahzad Sardar

Jason Gunn

Joachim Feldwisch

Konstantinos Linos

Eric Henderson

Brian Pogue

Keith Paulsen

Affiliations

Soon will be listed here.

Abstract

Microdose administration of ABY-029, an anti-epidermal growth factor receptor Affibody molecule conjugated to IRDye 800CW, is being studied in a Phase 0 trial for resection of soft-tissue sarcomas. The excised tissue of a single patient in the microdose administration group was imaged with both a wide-field fluorescence surgical system and a flat-bed scanning fluorescence imaging system. Here the resultant fluorescence from a breadloaf section of the primary tumor specimen and six region-specific tissue samples collected from that breadloaf are compared using these two imaging systems - a flatbed, black-box, fluorescence scanning system, the Odyssey CLx, and a open-air, wide-field, pre-clinical surgical imaging system, the Solaris. Florescence signal is compared using a variety of methods including: mean, standard deviation, variance, tumor-to-background ratio, biological-variance ratio, and contrast-to-noise ratio. The images produced from the Odyssey scanner have higher signal variance but more accurately represent the EGFR expression in small tissue sections. The Solaris system has higher depth sensitivity and volume averaging, and as such has lower signal variation and higher contrast-to-noise ratio.

Citing Articles

Illuminating the future of precision cancer surgery with fluorescence imaging and artificial intelligence convergence.

Cheng H, Xu H, Peng B, Huang X, Hu Y, Zheng C NPJ Precis Oncol. 2024; 8(1):196.

PMID: 39251820 PMC: 11385925. DOI: 10.1038/s41698-024-00699-3.

Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy.

Eissler N, Altena R, Alhuseinalkhudhur A, Bragina O, Feldwisch J, Wuerth G Biomedicines. 2024; 12(5).

PMID: 38791050 PMC: 11118066. DOI: 10.3390/biomedicines12051088.

Fluorescence molecular optomic signatures improve identification of tumors in head and neck specimens.

Chen Y, Streeter S, Hunt B, Sardar H, Gunn J, Tafe L Front Med Technol. 2023; 5:1009638.

PMID: 36875185 PMC: 9975724. DOI: 10.3389/fmedt.2023.1009638.

Molecular and functional imaging in cancer-targeted therapy: current applications and future directions.

Bai J, Qiu S, Zhang G Signal Transduct Target Ther. 2023; 8(1):89.

PMID: 36849435 PMC: 9971190. DOI: 10.1038/s41392-023-01366-y.

High-Contrast Detection of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery.

Vargas S, AghaAmiri S, Ghosh S, Luciano M, Borbon L, Ear P Mol Pharm. 2022; 19(11):4241-4253.

PMID: 36174110 PMC: 9830638. DOI: 10.1021/acs.molpharmaceut.2c00583.

References

Pisters P, Leung D, Woodruff J, Shi W, Brennan M . Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996; 14(5):1679-89. DOI: 10.1200/JCO.1996.14.5.1679. View

Samkoe K, Tichauer K, Gunn J, Wells W, Hasan T, Pogue B . Quantitative in vivo immunohistochemistry of epidermal growth factor receptor using a receptor concentration imaging approach. Cancer Res. 2014; 74(24):7465-74. PMC: 4268352. DOI: 10.1158/0008-5472.CAN-14-0141. View

Mito J, Ferrer J, Brigman B, Lee C, Dodd R, Eward W . Intraoperative detection and removal of microscopic residual sarcoma using wide-field imaging. Cancer. 2012; 118(21):5320-30. PMC: 3532657. DOI: 10.1002/cncr.27458. View

Samkoe K, Bates B, Tselepidakis N, DSouza A, Gunn J, Ramkumar D . Development and evaluation of a connective tissue phantom model for subsurface visualization of cancers requiring wide local excision. J Biomed Opt. 2017; 22(12):1-12. PMC: 5741805. DOI: 10.1117/1.JBO.22.12.121613. View

Tichauer K, Holt R, Samkoe K, El-Ghussein F, Gunn J, Jermyn M . Computed tomography-guided time-domain diffuse fluorescence tomography in small animals for localization of cancer biomarkers. J Vis Exp. 2012; (65):e4050. PMC: 3476420. DOI: 10.3791/4050. View

Samkoe K, Gunn J, Marra K, Hull S, Moodie K, Feldwisch J . Toxicity and Pharmacokinetic Profile for Single-Dose Injection of ABY-029: a Fluorescent Anti-EGFR Synthetic Affibody Molecule for Human Use. Mol Imaging Biol. 2016; 19(4):512-521. PMC: 5648591. DOI: 10.1007/s11307-016-1033-y. View

Schindelin J, Rueden C, Hiner M, Eliceiri K . The ImageJ ecosystem: An open platform for biomedical image analysis. Mol Reprod Dev. 2015; 82(7-8):518-29. PMC: 5428984. DOI: 10.1002/mrd.22489. View

Yano S, Miwa S, Kishimoto H, Urata Y, Tazawa H, Kagawa S . Eradication of osteosarcoma by fluorescence-guided surgery with tumor labeling by a killer-reporter adenovirus. J Orthop Res. 2015; 34(5):836-44. DOI: 10.1002/jor.23073. View

Pogue B, Paulsen K, Hull S, Samkoe K, Gunn J, Hoopes J . Advancing Molecular-Guided Surgery through probe development and testing in a moderate cost evaluation pipeline. Proc SPIE Int Soc Opt Eng. 2015; 9311. PMC: 4405779. DOI: 10.1117/12.2083224. View

10.

Holt D, Parthasarathy A, Okusanya O, Keating J, Venegas O, Deshpande C . Intraoperative near-infrared fluorescence imaging and spectroscopy identifies residual tumor cells in wounds. J Biomed Opt. 2015; 20(7):76002. PMC: 4497968. DOI: 10.1117/1.JBO.20.7.076002. View

11.

Rosenthal E, Warram J, de Boer E, Chung T, Korb M, Brandwein-Gensler M . Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer. Clin Cancer Res. 2015; 21(16):3658-66. PMC: 4909371. DOI: 10.1158/1078-0432.CCR-14-3284. View

12.

Yano S, Miwa S, Kishimoto H, Uehara F, Tazawa H, Toneri M . Targeting tumors with a killer-reporter adenovirus for curative fluorescence-guided surgery of soft-tissue sarcoma. Oncotarget. 2015; 6(15):13133-48. PMC: 4537004. DOI: 10.18632/oncotarget.3811. View

13.

Uehara F, Hiroshima Y, Miwa S, Tome Y, Yano S, Yamamoto M . Fluorescence-guided surgery of retroperitoneal-implanted human fibrosarcoma in nude mice delays or eliminates tumor recurrence and increases survival compared to bright-light surgery. PLoS One. 2015; 10(2):e0116865. PMC: 4339719. DOI: 10.1371/journal.pone.0116865. View

14.

Moore L, Rosenthal E, de Boer E, Prince A, Patel N, Richman J . Effects of an Unlabeled Loading Dose on Tumor-Specific Uptake of a Fluorescently Labeled Antibody for Optical Surgical Navigation. Mol Imaging Biol. 2016; 19(4):610-616. PMC: 5679006. DOI: 10.1007/s11307-016-1022-1. View

15.

Miwa S, Hiroshima Y, Yano S, Zhang Y, Matsumoto Y, Uehara F . Fluorescence-guided surgery improves outcome in an orthotopic osteosarcoma nude-mouse model. J Orthop Res. 2014; 32(12):1596-601. PMC: 4198468. DOI: 10.1002/jor.22706. View

16.

Scheuer W, van Dam G, Dobosz M, Schwaiger M, Ntziachristos V . Drug-based optical agents: infiltrating clinics at lower risk. Sci Transl Med. 2012; 4(134):134ps11. DOI: 10.1126/scitranslmed.3003572. View

17.

Samkoe K, Bates B, Elliott J, LaRochelle E, Gunn J, Marra K . Application of Fluorescence-Guided Surgery to Subsurface Cancers Requiring Wide Local Excision: Literature Review and Novel Developments Toward Indirect Visualization. Cancer Control. 2018; 25(1):1073274817752332. PMC: 5933571. DOI: 10.1177/1073274817752332. View

18.

Sato O, Wada T, Kawai A, Yamaguchi U, Makimoto A, Kokai Y . Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases. Cancer. 2005; 103(9):1881-90. DOI: 10.1002/cncr.20986. View

19.

Javid Whitley M, Cardona D, Lazarides A, Spasojevic I, Ferrer J, Cahill J . A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. Sci Transl Med. 2016; 8(320):320ra4. PMC: 4794335. DOI: 10.1126/scitranslmed.aad0293. View

20.

Bowden L, Booher R . The principles and technique of resection of soft parts for sarcoma. 1958. Clin Orthop Relat Res. 2004; (426):5-10. DOI: 10.1097/01.blo.0000141673.52701.4f. View